Loading…
CLONAZEPAM ROSEMONT is a brand name for Clonazepam. The medicine, its uses, side effects and dosage are the same regardless of brand.
Used for: All clinical forms of epileptic disease and seizures in adults, especially absence seizures (petit mal) including atypical absence; primary or secondarily generalised tonic-clonic (grand mal), tonic or clonic seizures; partial (focal) seizures with elementary or complex symptomatology; various forms of myoclonic…
Verbatim from this product's MHRA label. Tap a section to expand.
5mg/5ml oral solution may facilitate the administration of lower daily doses in the initial stages of treatment or treatment for the elderly. The 2mg/5ml oral solution should be used for maintenance and maximum dosage regimens. Adults Initial dosage should not exceed 1mg/day.
The maintenance dosage for adults normally falls within the range 4 to 8mg. Elderly The elderly are particularly sensitive to the effects of centrally depressant drugs and may experience confusion. 5mg/day. These are total daily dosages which should be divided into 4 doses taken at intervals throughout the day.
If necessary, larger doses may be given at the discretion of the physician, up to a maximum of 20mg daily. The maintenance dose should be attained after 2 to 4 weeks of treatment. Paediatric Population Due to the presence of ethanol in the formulation, this product is not indicated for paediatric use.
25ml graduation is supplied with the pack. Suitable for administration via non-PVC nasogastric (NG) or percutaneous endoscopic gastrostomy (PEG) tubes. 6. When these instructions are followed over 95% of the dose is delivered. The product is incompatible with polystyrene or PVC and therefore, other devices may react with the product.
It should be noted that for oral syringes, the product may cause the plunger to stop moving smoothly or the markings may fade over time. Treatment should be started with low doses. The dose may be increased progressively until the maintenance dose suited to the individual patient has been found.
The dosage of clonazepam must be adjusted to the needs of each individual and depends on the individual response to therapy. The maintenance dosage must be determined according to clinical response and tolerance. The daily dose should be divided into 4 equal doses.
If doses are not equally divided, the largest dose should be given before retiring. Once the maintenance dose level has been reached, the daily amount may be given in a single dose in the evening. Simultaneous administration of more than one antiepileptic drug is a common practice in the treatment of epilepsy and may be undertaken with clonazepam.
The dosage of each drug may be required to be adjusted to obtain the optimum effect. If status epilepticus occurs in a patient receiving oral clonazepam, administration of an intravenous clonazepam injection may still control the status.
Immune System Disorders Allergic reactions and very few cases of anaphylaxis and angioedema have been reported to occur with benzodiazepines. Endocrine Disorders Isolated cases of reversible development of premature secondary sex characteristics in children (incomplete precocious puberty) have been reported.
Psychiatric Disorders Impaired concentration, restlessness, emotional and mood disturbances, confusional state and disorientation have been observed. Depression may occur in patients treated with Clonazepam, but it may be also associated with the underlying disease.
The following paradoxical reactions have been observed: excitability, irritability, aggression, agitation, nervousness, hostility, anxiety, sleep disturbances, nightmares, vivid dreams, restlessness, hallucinations and psychotic disorders and activation of new types of seizures may be precipitated.
If these occur, the benefit of continuing the drug should be weighed against the adverse effect. The addition to the regimen of another suitable drug may be necessary or, in some cases, it may be advisable to discontinue clonazepam therapy.
In rare cases loss of libido may occur. Clonazepam generally has a beneficial effect on behaviour disturbances in epileptic patients. Paradoxical reactions are more likely to occur in children and in the elderly. Nervous System Disorders Somnolence, slowed reaction, muscular hypotonia, dizziness, ataxia, light- headedness, co-ordination disturbances, fatigue and muscle weakness.
These undesirable effects occur relatively frequently and are usually transient and generally disappear spontaneously in the course of the treatment or on reductions of the dosage. They can be partially prevented by increasing the dose slowly at the start of treatment.
Headache was observed in rare cases. Causing of generalized fits was observed very rarely. Particularly in long-term or high-dose treatment, reversible disorders such as a slowing or slurring of speech (dysarthria), reduced co-ordination of movements and gait (ataxia) and nystagmus may occur.
Suicidal ideation and behaviour have been reported in patients treated with anti- epileptic agents in several indications. A meta-analysis of randomised placebo controlled trials of anti-epileptic drugs has also shown a small increased risk of suicidal ideation and behaviour.
The mechanism of this risk is not known and the available data do not exclude the possibility of an increased risk for clonazepam. Therefore patients should be monitored for signs of suicidal ideation and behaviours and appropriate treatment should be considered.
Patients (and caregivers of patients) should be advised to seek medical advice should signs of suicidal ideation or behaviour emerge. Patients with a history of depression and/or suicide attempts should be kept under close supervision.
Clonazepam should be used with caution in patients with chronic pulmonary insufficiency, or with impairment of renal or hepatic function, and in the elderly or the debilitated. In these cases dosage should generally be reduced. As with all other antiepileptic drugs, treatment with clonazepam even if of short duration, must not be abruptly interrupted, but must be withdrawn by gradually reducing the dose in view of the risk of precipitating status epilepticus.
In such cases a combination with other antiepileptics is indicated. This precaution must also be taken when withdrawing another drug while the patient is still receiving clonazepam therapy. Some loss of effect may occur during the course of clonazepam long-term treatment.
Prolonged use of benzodiazepines may result in dependence development with withdrawal symptoms on cessation of use. Clonazepam may be used only with particular caution in patients with spinal or cerebellar ataxia, in the event of acute intoxication with alcohol.
Hepatic impairment Benzodiazepines may have a contributory role in precipitating episodes of hepatic encephalopathy in severe hepatic impairment. 3). Myasthenia gravis As with any substance with CNS depressant and/or muscle-relaxant properties, particular care should be taken when administering clonazepam to patients with myasthenia gravis.
1; acute pulmonary insufficiency; severe respiratory insufficiency, sleep apnoea syndrome, myasthenia gravis, severe hepatic insufficiency as benzodiazepines may precipitate hepatic encephalopathy. Clonazepam must not be used in patients in a coma, or in patients known to be abusing pharmaceuticals, drugs or alcohol.
Not medical advice. Always read the patient information leaflet and follow your prescriber or pharmacist.
Other brands of Clonazepam in United Kingdom.
Know a brand we are missing in United Kingdom? Suggest a brand →
Brand names are compiled from public regulatory records for active-ingredient mapping only. Drugvu is not affiliated with any manufacturer. This is not medical advice.
Before adding clonazepam to an existing anticonvulsant regimen, it should be considered that the use of multiple anticonvulsants may result in an increase of undesired effects.
Anterograde amnesia may occur using benzodiazepines at therapeutic dosages, the risks increasing at higher dosages. Amnestic effects may be associated with inappropriate behavior. With certain forms of epilepsy, an increase in the frequency of seizures during long-term treatment is possible.
Eye Disorders Particularly in long-term or high-dose treatment, reversible disorders of vision (diplopia) may occur. Common: nystagmus Cardiac Disorders Cardiac failure including cardiac arrest has been reported. Respiratory, Thoracic and Mediastinal System Disorders Rarely respiratory depression may occur with intravenous clonazepam, particularly if pre-existing airways obstruction or brain damage or if other depressant drugs have been administered.
As a rule, this effect can be avoided by careful adjustment of the dose in individual requirements. In infants and small children, and particularly those with a degree of mental impairment, clonazepam may give rise to salivary or bronchial hypersecretion with drooling.
Supervision of the airway may be required. Gastrointestinal Disorders The following effects have been reported in rare cases: nausea, gastrointestinal and epigastric symptoms. Skin and Subcutaneous Tissue Disorders The following effects may occur in rare cases: urticaria, pruritus, rash, transient hair loss, pigmentation changes and angioedema.
Musculoskeletal and Connecting Tissue Disorders Muscle weakness, this undesirable effect occurs relatively frequently and is usually transient and generally disappears spontaneously in the course of the treatment or on reduction of the dosage.
It can be partially prevented by increasing the dose slowly at the start of the treatment. Renal and Urinary Disorders In rare cases urinary incontinence may occur. Reproductive System and Breast Disorders In rare cases erectile dysfunction, decrease in sexual drive (loss of libido) and impotence may occur.
General Disorders and Administration Site Conditions Fatigue (tiredness, lassitude), this undesirable effect occurs relatively frequently and is usually transient and generally disappears spontaneously in the course of the treatment or on reduction of the dosage.
It can be partially prevented by increasing the dose slowly at the start of treatment. Paradoxical reactions including irritability have been observed (see also psychiatric disorders). Injury, Poisoning and Procedural Complications There have been reports of falls and fractures in benzodiazepine users.
The risk is increased in those taking concomitant sedatives (including alcoholic beverages) and in the elderly. Investigations In rare case decreased platelet count may occur. Isolated cases of blood dyscrasias and abnormal liver function tests have been reported.
4) Although Clonazepam has been given uneventfully to patients with porphyria, rarely it may induce convulsions in these patients. Reporting of suspected adverse reactions Reporting suspected adverse reactions after authorisation of the medicinal product is important.
It allows continued monitoring of the benefit/risk balance of the medicinal product. uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.
The concomitant use of clonazepam with alcohol or/and CNS depressants should be avoided. 9). Clonazepam should be used with extreme caution in patients with a history of alcohol or drug abuse. g. 5). Effects on the respiratory system may be aggravated by pre-existing airways obstruction or brain damage or if other medications which depress respiration have been given.
As a rule, this effect can be avoided by careful adjustment of the dose to individual requirements. Clonazepam is considered to be probably non-porphyrinogenic, although there is some conflicting evidence. Therefore in patients with porphyria, clonazepam should be used with care.
g. 7). As a general rule, epileptic patients are not allowed to drive. Even when adequately controlled on clonazepam, it should be remembered that any increase in dosage or alteration in timings of dosage may modify patients’ reactions, depending on individual susceptibility.
In cases of loss or bereavement, psychological adjustment may be inhibited by benzodiazepines. Benzodiazepines are not recommended for the primary treatment of psychotic illness. 8). Should this occur, the use of the drug should be discontinued.
Paradoxical reactions are more likely to occur in children and in the elderly. 3). 8). In particular long-term or high- dose treatment, may lead to reversible disorders such as dysarthria, reduced coordination of movements and gait disorder (ataxia), nystagmus and vision (diplopia).
Furthermore, the risk of anterograde amnesia, which may occur using benzodiazepines at therapeutic dosages, increases at higher dosages. Amnestic effects may be associated with inappropriate behaviour. 8) during long-term treatment is possible.
The risk of dependence increases with dose and duration of treatment and is particularly pronounced in predisposed patients with a history of alcoholism and/or drug abuse. Once physical dependence has developed, abrupt termination of treatment will be accompanied by withdrawal symptoms.
During long-term treatment, withdrawal symptoms may develop after a lengthy period of use, especially with high doses or if the daily dose is reduced rapidly or abruptly discontinued. The symptoms include tremor, sweating, agitation, sleep disturbances and anxiety, headaches, […]